Bristol Myers Squibb announced on May 29, 2026 that mezigdomide, a cereblon E3 ligase modulator (CELMoD) agent, reduced disease progression or death risk by 52% in the SUCCESSOR-2 trial of relapsed/refractory multiple myeloma patients. Median progression-free survival reached 18 months versus 8.3 months for standard treatment alone. The experimental oral drug achieved an 80.2% overall response rate when combined with carfilzomib and dexamethasone.
SUCCESSOR-2 trial results
▪Median progression-free survival was 18 months for patients who received mezigdomide in the SUCCESSOR-2 trial versus 8.3 months for the control arm.
▪Overall survival data from the SUCCESSOR-2 trial is not yet available as of May 29, 2026.
▪The overall response rate was 80.2% for patients on the mezigdomide regimen in the SUCCESSOR-2 trial, while 53.4% responded to the standard therapy.
▪83.7% of mezigdomide patients in the SUCCESSOR-2 trial had significant adverse events compared with 56.5% for the control group.
▪27% of patients who received mezigdomide in the SUCCESSOR-2 trial had a complete response, roughly triple the number compared to the control group.
▪Bristol Myers Squibb announced on May 29, 2026 that mezigdomide delayed disease progression in a late-stage trial of multiple myeloma patients whose illness had relapsed or not responded to other treatments.
▪The SUCCESSOR-2 trial results are being presented at the annual American Society of Clinical Oncology meeting in Chicago in May 2026.
▪Bristol Myers Squibb's SUCCESSOR-2 trial showed that mezigdomide added to carfilzomib and dexamethasone reduced the risk of disease progression or death by 52% compared to the standard treatment alone in multiple myeloma patients.
Mezigdomide drug mechanism
▪Iberdomide is another myeloma treatment Bristol Myers Squibb is developing that belongs to the cereblon E3 ligase modulator (CELMoD) class of drugs.
▪Mezigdomide is an experimental oral drug developed by Bristol Myers Squibb.
▪The most common adverse event from mezigdomide treatment was neutropenia, abnormally low levels of a type of white blood cell.
▪Mezigdomide belongs to a class of drugs called cereblon E3 ligase modulator (CELMoD) agents.
▪Mezigdomide, as an oral medicine, could easily be used in community oncology clinics where most myeloma patients are treated.
Generic competition replacement strategy
▪The U.S. FDA is expected to make an approval decision on iberdomide in August 2026.
▪Carfilzomib is sold as Kyprolis by Amgen.
▪Bristol Myers Squibb sees mezigdomide and iberdomide replacing older Bristol Myers Squibb medicines Revlimid and Pomalyst, which are facing generic competition, in later lines of treatment.
Story comments
Loading comments…